Pacira BioSciences, Inc. (PCRX)
USD 24.38
(2.91%)
USD 24.38
(2.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 432.74 Million USD | -34.36% |
| 2022 | 659.25 Million USD | 21.35% |
| 2021 | 543.27 Million USD | 23.14% |
| 2020 | 441.17 Million USD | 61.19% |
| 2019 | 273.69 Million USD | 72.78% |
| 2018 | 158.4 Million USD | -28.77% |
| 2017 | 222.37 Million USD | 205.48% |
| 2016 | 72.79 Million USD | 237.25% |
| 2015 | -53.03 Million USD | 3.69% |
| 2014 | -55.06 Million USD | -163.7% |
| 2013 | 86.44 Million USD | 623.12% |
| 2012 | -16.52 Million USD | 7.35% |
| 2011 | -17.83 Million USD | -1548.43% |
| 2010 | -1.08 Million USD | 84.71% |
| 2009 | -7.07 Million USD | 42.86% |
| 2008 | -12.38 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 397.72 Million USD | -8.09% |
| 2024 Q2 | 401.54 Million USD | 0.96% |
| 2023 Q1 | 589.61 Million USD | -10.56% |
| 2023 Q3 | 491.17 Million USD | -8.0% |
| 2023 Q2 | 533.9 Million USD | -9.45% |
| 2023 FY | 432.74 Million USD | -34.36% |
| 2023 Q4 | 432.74 Million USD | -11.9% |
| 2022 Q3 | 712.21 Million USD | 0.41% |
| 2022 Q4 | 659.25 Million USD | -7.44% |
| 2022 FY | 659.25 Million USD | 21.35% |
| 2022 Q1 | 774.4 Million USD | 42.54% |
| 2022 Q2 | 709.3 Million USD | -8.41% |
| 2021 Q3 | 420.52 Million USD | -5.18% |
| 2021 FY | 543.27 Million USD | 23.14% |
| 2021 Q1 | 477.45 Million USD | 8.22% |
| 2021 Q4 | 543.27 Million USD | 29.19% |
| 2021 Q2 | 443.49 Million USD | -7.11% |
| 2020 Q1 | 299.64 Million USD | 9.48% |
| 2020 Q2 | 317.13 Million USD | 5.84% |
| 2020 Q3 | 411.12 Million USD | 29.64% |
| 2020 Q4 | 441.17 Million USD | 7.31% |
| 2020 FY | 441.17 Million USD | 61.19% |
| 2019 Q3 | 260.86 Million USD | -8.04% |
| 2019 Q4 | 273.69 Million USD | 4.92% |
| 2019 Q2 | 283.66 Million USD | 148.39% |
| 2019 Q1 | 114.2 Million USD | -27.91% |
| 2019 FY | 273.69 Million USD | 72.78% |
| 2018 Q4 | 158.4 Million USD | 181.43% |
| 2018 FY | 158.4 Million USD | -28.77% |
| 2018 Q3 | 56.28 Million USD | -66.24% |
| 2018 Q2 | 166.71 Million USD | -30.08% |
| 2018 Q1 | 238.44 Million USD | 7.23% |
| 2017 Q2 | 215.83 Million USD | 36.79% |
| 2017 Q1 | 157.78 Million USD | 116.75% |
| 2017 Q3 | 246.82 Million USD | 14.36% |
| 2017 FY | 222.37 Million USD | 205.48% |
| 2017 Q4 | 222.37 Million USD | -9.91% |
| 2016 FY | 72.79 Million USD | 237.25% |
| 2016 Q1 | 70.18 Million USD | 232.33% |
| 2016 Q3 | 83.12 Million USD | 2.52% |
| 2016 Q4 | 72.79 Million USD | -12.42% |
| 2016 Q2 | 81.07 Million USD | 15.52% |
| 2015 Q1 | -50.75 Million USD | 7.84% |
| 2015 Q4 | -53.03 Million USD | -171.3% |
| 2015 FY | -53.03 Million USD | 3.69% |
| 2015 Q2 | 71.16 Million USD | 240.22% |
| 2015 Q3 | 74.38 Million USD | 4.53% |
| 2014 Q2 | -7.16 Million USD | -120.24% |
| 2014 Q4 | -55.06 Million USD | -165.32% |
| 2014 Q1 | 35.42 Million USD | -59.02% |
| 2014 FY | -55.06 Million USD | -163.7% |
| 2014 Q3 | 84.3 Million USD | 1276.02% |
| 2013 Q4 | 86.44 Million USD | -8.57% |
| 2013 FY | 86.44 Million USD | 623.12% |
| 2013 Q3 | 94.54 Million USD | 152590.32% |
| 2013 Q2 | -62 Thousand USD | -100.09% |
| 2013 Q1 | 69.58 Million USD | 521.09% |
| 2012 Q4 | -16.52 Million USD | -192.12% |
| 2012 Q1 | 2.44 Million USD | 113.71% |
| 2012 FY | -16.52 Million USD | 7.35% |
| 2012 Q2 | 3.22 Million USD | 31.85% |
| 2012 Q3 | 17.93 Million USD | 456.25% |
| 2011 Q4 | -17.83 Million USD | -296.6% |
| 2011 Q2 | 1.45 Million USD | 104.26% |
| 2011 Q1 | -34.19 Million USD | -3060.17% |
| 2011 Q3 | 9.07 Million USD | 523.08% |
| 2011 FY | -17.83 Million USD | -1548.43% |
| 2010 Q3 | 41.69 Million USD | 719.74% |
| 2010 FY | -1.08 Million USD | 84.71% |
| 2010 Q4 | -1.08 Million USD | -102.59% |
| 2010 Q2 | -6.72 Million USD | 0.0% |
| 2009 FY | -7.07 Million USD | 42.86% |
| 2009 Q4 | -7.07 Million USD | 0.0% |
| 2008 FY | -12.38 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -23396.789% |
| Alpha Teknova, Inc. | 1.97 Million USD | -21822.29% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -359.357% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -477.38% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 0.595% |
| Cosmos Health Inc. | 8.59 Million USD | -4937.344% |
| Journey Medical Corporation | -9.7 Million USD | 4557.163% |
| Embecta Corp. | 1.31 Billion USD | 67.016% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 5.658% |
| Dynavax Technologies Corporation | 106.63 Million USD | -305.82% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 430.772% |
| PainReform Ltd. | -7.95 Million USD | 5543.346% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2867.866% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 2867.866% |
| SCYNEXIS, Inc. | -19.35 Million USD | 2336.413% |
| Safety Shot Inc | -2.28 Million USD | 19043.737% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 4689.165% |
| Procaps Group, S.A. | 242.93 Million USD | -78.135% |
| Theratechnologies Inc. | 24.87 Million USD | -1639.962% |
| Harrow Health, Inc. | 116.41 Million USD | -271.721% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 17272.46% |
| Biofrontera Inc. | 4.05 Million USD | -10569.28% |
| DURECT Corporation | -7.65 Million USD | 5753.854% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1390.739% |
| Cronos Group Inc. | -663.32 Million USD | 165.239% |
| OptiNose, Inc. | 58.06 Million USD | -645.279% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 30.581% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 3069.709% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 8444.455% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -2782.475% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 6904.561% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -404869.165% |
| Radius Health, Inc. | 359.28 Million USD | -20.448% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -219335.218% |
| ProPhase Labs, Inc. | 19.23 Million USD | -2150.252% |
| Phibro Animal Health Corporation | 454.84 Million USD | 4.859% |
| Procaps Group S.A. | 242.93 Million USD | -78.135% |
| Alvotech | 1.06 Billion USD | 59.34% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -11665.797% |
| Viatris Inc. | 17.13 Billion USD | 97.474% |
| Rockwell Medical, Inc. | 4.45 Million USD | -9611.535% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 8973.201% |
| SIGA Technologies, Inc. | -148.68 Million USD | 391.055% |
| Tilray Brands, Inc. | 158.97 Million USD | -172.207% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -255.007% |
| Shineco, Inc. | 29.29 Million USD | -1377.438% |
| PetIQ, Inc. | 351.93 Million USD | -22.963% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 15014.932% |
| Incannex Healthcare Limited | -5.48 Million USD | 7989.626% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -144.076% |
| Alimera Sciences, Inc. | 55.3 Million USD | -682.415% |
| Silver Spike Investment Corp. | -32.61 Million USD | 1426.968% |
| Assertio Holdings, Inc. | -32.52 Million USD | 1430.339% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 29168.288% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 8651.644% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 9089.323% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5368.731% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -10161.94% |
| Hempacco Co., Inc. | 13.61 Million USD | -3078.525% |
| Talphera, Inc. | -5.72 Million USD | 7664.167% |
| Alvotech | 1.06 Billion USD | 59.34% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -5956.627% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 547.468% |
| Currenc Group, Inc. | -16.57 Million USD | 2711.131% |
| Kamada Ltd. | -46.43 Million USD | 1032.009% |
| Indivior PLC | -33.95 Million USD | 1374.582% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -165974.129% |
| Flora Growth Corp. | -713 Thousand USD | 60793.689% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5368.731% |
| Evolus, Inc. | 63.7 Million USD | -579.265% |
| HUTCHMED (China) Limited | -197.45 Million USD | 319.159% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 9.677% |
| Akanda Corp. | 3.9 Million USD | -10982.082% |